[1]Saeedi Borujeni MJ, Esfandiary E, Taheripak G, et al. Molecular aspects of diabetes mellitus: resistin, microRNA, and exosome\[J\]. J Cell Biochem,2018,119(2):1257-1272.
[2]International Diabetes Federation(IDF).Latest figures show 463 million people now living with diabetes worldwide as numbers continue to rise[J]. Diabetes Res Clin Pract, 2019,157:107932.
[3]Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go\[J\]. Cell, 2016, 164(6):1226-1232.
[4]Guillaume V, Gisela D, Graca R. Shedding light on the cell biology of extracellular vesicles\[J\]. Nat Rev Mol Cell Biol,2018, 19(4):213-228.
[5]Fanny M, Gregory F, Jan A, et al. Preclinical translation of exosomes derived from mesenchymal stem/stromal cells\[J\]. Stem cells,2020, 38(1):15-21.
[6]许文荣,孙瑶湘.外泌体内分子标志物检测及其临床应用\[J\].临床检验杂志,2017,35(3): 161-164.
[7]Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes\[J\]. Science,2020,367(6478):eaau6977.
[8]Farooqi AA, Desai NN, Qureshi MZ, et al. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds\[J\]. Biotechnol Adv,2018,36(1):328-334.
[9]Deng ZB, Poliakov A, Hardy RW, et al. Adipose tissue exosomelike vesicles mediate activation of macrophageinduced insulin resistance\[J\]. Diabetes,2009,58(11):2498-2505.
[10]寿崟,马宇,航虎力,等.外泌体在糖尿病及其并发症的发生、发展和诊治中的作用\[J\]. 生理学报, 2019,71(6): 917-934.
[11]Guay C, Regazzi R. Exosomes as new players in metabolic organ crosstalk\[J\]. Diabetes Obes Metab,2017,19(Suppl 1):137-146.
[12]GarciaContreras M, Brooks RW, Boccuzzi L, et al. Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus\[J\]. Eur Rev Med Pharmacol Sci,2017,21(12):2940-2956.
[13]Cianciaruso C, Phelps EA, Pasquier M, et al. Primary human and rat βcells release the intracellular autoantigens GAD65, IA2, and proinsulin in exosomes together with cytokineinduced enhancers of immunity\[J\]. Diabetes,2017,66(2):460-473.
[14]La Marca V, Fierabracci A. Insights into the diagnostic potential of extracellular vesicles and their miRNA signature from liquid biopsy as early biomarkers of diabetic micro/macrovascular complications\[J\]. Int J Mol Sci,2017,18(9):1974.
[15]Salem MA, Adly AA, Ismail EA, et al. Platelets microparticles as a link between micro and macroangiopathy in young patients with type 1 diabetes\[J\]. Platelets,2015,26(7):682-688.
[16]Castao C, Novials A, Párrizas M. Exosomes and diabetes\[J\]. Diabetes Metab Res Rev,2019,35(3):e3107.
[17]He Q, Wang L, Zhao R, et al. Mesenchymal stem cellderived exosomes exert ameliorative effects in type 2 diabetes by improving hepatic glucose and lipid metabolism via enhancing autophagy\[J\]. Stem Cell Res Ther,2020,11(1):223.
[18]Tsukita S, Yamada T, Takahashi K, et al. MicroRNAs 106b and 222 improve hyperglycemia in a mouse model of insulindeficient diabetes via pancreatic βcell proliferation\[J\]. Ebio Medicine,2017,15:163-172.
[19]Abe H, Sakurai A, Ono H, et al. Urinary exosomal mRNA of WT1 as diagnostic and prognostic biomarker for diabetic nephropathy\[J\]. J Med Invest,2018,65(4):208-215.
[20]Zhang SJ, Chen X, Li CP, et al. Identification and characterization of circular RNAs as a new class of putative biomarkers in diabetes retinopathy\[J\]. Invest Ophthalmol Vis Sci, 2017,58(14):6500-6509.
[21]Safwat A, Sabry D, Ragiae A, et al. Adipose mesenchymal stem cellsderived exosomes attenuate retina degeneration of streptozotocininduced diabetes in rabbits\[J\]. J Circ Biomark, 2018,7:1-10.
[22]Ebrahim N, Ahmed IA, Hussien NI, et al. Mesenchymal stem cellderived exosomes ameliorated diabetic nephropathy by autophagy induction through the mTOR signaling pathway\[J\]. Cells,2018,7(12):226.
[23]Barutta F, Tricarico M, Corbelli A, et al. Urinary exosomal microRNAs in incipient diabetic nephropathy\[J\]. PLoS One,2013,8(11):e73798.
[24]Li H, Rong P, Ma X, et al. Mouse umbilical cord mesenchymal stem cell paracrine alleviates renal fibrosis in diabetic nephropathy by reducing myofibroblast transdifferentiation and cell proliferation and upregulating MMPs in mesangial cells\[J\]. J Diabetes Res, 2020,2020:3847171.
[25]Davidson SM, Takov K, Yellon DM. Exosomes and cardiovascular protection\[J\]. Cardiovasc Drugs Ther,2017,31(1):77-86.
[26]Davidson SM, Riquelme JA, Takov K, et al. Cardioprotection mediated by exosomes is impaired in the setting of type Ⅱ diabetes but can be rescued by the use of nondiabetic exosomes in vitro\[J\]. J Cell Mol Med,2018,22(1):141-151.
[27]Rani S, Ryan AE, Griffin MD, et al. Mesenchymal stem cellderived extracellular vesicles: toward cellfree therapeutic applications\[J\]. Mol Ther,2015,23(5):812-823.
[28]Ying W, Riopel M, Bandyopadhyay G, et al. Adipose tissue macrophagederived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity\[J\]. Cell, 2017,171(2):372-384.
[29]Thomou T, Mori MA, Dreyfuss JM, et al. Adiposederived circulating miRNAs regulate gene expression in other tissues\[J\]. Nature, 2017,542(7642):450-455.
|